1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH Research Education Program (R25) is sponsored by National Institute of Neurological Disorders and Stroke (NINDS). This program supports neuroscience research education programs in all areas (basic, clinical, and translational) that will significantly advance the mission of NINDS. While not exclusively RDoC, it can support training that incorporates RDoC principles in neuroscience research.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U.S. domestic institutions, established investigators. Programs must be designed to include participants drawn from a national audience and provide a critical educational experience not already available at a local or national level. Confirm the full requirements in the official notice before applying.
NIH Research Education Program (R25) is funded by National Institute of Neurological Disorders and Stroke (NINDS). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
The AIR program is ARPA-H's most ambitious bet yet: fully autonomous robots that perform stroke-saving thrombectomies without a human surgeon. Proposals are due March 18. A strategic guide for applicants.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read article